Author:
Charlton R. A.,Bettoli V.,Bos H. J.,Engeland A.,Garne E.,Gini R.,Hansen A. V.,de Jong-van den berg L. T. W.,Jordan S.,Klungsøyr K.,Neville A. J.,Pierini A.,Puccini A.,Sinclair M.,Thayer D.,Dolk H.
Funder
Seventh Framework Programme
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine
Reference44 articles.
1. European Medicine Agency (EMA) (2017) Guideline on good pharmacovigilance practices (GVP) module V—risk management systems (Rev 2). [cited 2017 05 July]; Available from:
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129134.pdf
2. European Medicines Agency (2015) Towards optimising risk minimisation measures. Available from
http://www.ema.europa.eu/docs/en_GB/document_library/Report/2015/12/WC500198810.pdf
. Accessed 07.05.2017
3. Whitley L, Knight C, Gabbay F Risk minimisation and measuring effectiveness—the evolving challenge. Available from
www.transcrip-partners.com/files/download/78
. Accessed 07.07.2017
4. Lammer EJ, Chen DT, Hoar RM, Agnish ND, Benke PJ, Braun JT, Curry CJ, Fernhoff PM, Grix AW Jr, Lott IT, Richard JM, Sun SC (1985) Retinoic acid embryopathy. N Engl J Med 313(14):837–841.
https://doi.org/10.1056/NEJM198510033131401
5. McBride W (1961) Thalidomide and congenital abnormalities. Lancet 2:1358
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献